NewAmsterdam Pharma Co N.V.
NAMSW· Nasdaq
Released Nov 4, 2026, before the open
10-Q filed Nov 4, 2026, 35 days after period end · 0001193125-26-446228
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $19.16M | $348.00K | $29.11M | $2.94M |
| Net Income | -$17.39M | -$72.01M | -$16.65M | -$47.13M |
| EPS Diluted | -$0.14 |
NewAmsterdam Pharma Co N.V. · CIK 1936258 · Engraved from SEC EDGAR
| -$0.61 |
| -$0.18 |
| -$0.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.